Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2795602 | 0.93 | ALDH1A1 (0.42) | ALDH1A1KDM4EHTTSMN1; SMN2CHRM3 | |
| SCHEMBL2797791 | 0.93 | ALDH1A1 (0.47) | ALDH1A1KDM4EHTTSMN1; SMN2CHRM3 | |
| SCHEMBL2793297 | 0.87 | ALDH1A1 (0.43) | ALDH1A1KDM4EHTTSMN1; SMN2CHRM3 | |
| SCHEMBL4556284 | 0.79 | CHRM3 (0.38) | ALDH1A1SMN1; SMN2CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL2798000 | 0.78 | CHRM3 (0.37) | ALDH1A1CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL2795631 | 0.77 | ALDH1A1 (0.50) | ALDH1A1KDM4EHTTSMN1; SMN2CHRM3 | |
| SCHEMBL4556351 | 0.77 | CHRM3 (0.39) | ALDH1A1SMN1; SMN2CHRM3CHRM2CHRM1 | |
| SCHEMBL2793007 | 0.77 | ALDH1A1 (0.42) | ALDH1A1KDM4EHTTSMN1; SMN2FDPS | |
| Bromide SCHEMBL2791902 | 0.76 | CHRM3 (0.38) | ALDH1A1CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL16053656 | 0.75 | CHRM3 (0.47) | ALDH1A1CHRM3CHRM2CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168197-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-07-01 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | claimed |
| EP-2129663-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2009-12-09 | — | — | EP | claimed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | claimed |
| WO-2008104942-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2008-09-04 | — | — | WO | claimed |
| US-20100168197-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-07-01 | — | — | US | disclosed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| EP-2129663-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2009-12-09 | — | — | EP | disclosed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008104942-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168197-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | ALDH1A1 1927/4885KDM4E 3920/4885HTT 3592/4885 |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | ALDH1A1 2460/4885KDM4E 1748/4885HTT 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.